Advertisement
"MedImmune is working on a number of potential solutions for patients struggling with systemic autoimmune rheumatic diseases," said Barbara White, M.D., vice president, clinical development, respiratory, inflammation, and autoimmunity. "We are pleased to share promising basic research and translational science data relevant to the development of new treatments for diseases such as lupus, rheumatoid arthritis, and myositis"
Advertisement
MedImmune programs that will be discussed include:
MedImmune has a preclinical program investigating antibodies that target CXCL13 which may have the potential to prevent the generation of these inflammatory follicles within the rheumatic joint.
The schedule for MedImmune's eight research posters to be presented at the meeting, starting on Sunday October 26, is as follows:
About MedImmune
MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at www.medimmune.com.
-- MEDI-545 - MEDI-545 is a monoclonal antibody (MAb) targeting interferon-alpha, which regulates processes involved in autoimmune diseases. MedImmune has launched a broad development program with this molecule to assess its potential to treat or prevent a variety of immunological disorders. Currently, MedImmune is conducting a phase 2a trial in patients with systemic lupus erythematosus (SLE) and a phase 1b study in patients with active dermatomyositis and polymyositis. The company has also conducted clinical trials in psoriasis with MEDI-545. -- CAM-3001 - CAM-3001 is a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha sub-unit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). CAM-3001 is a phase 1 clinical stage program. -- ICOS - ICOS (Inducible costimulator) is a receptor on activated T-cells that plays a central role in humoral immunity. Elevated levels of ICOS are present in patients with autoimmune diseases and effector cytokines have been shown to correlate with increased levels of this protein. MedImmune has a preclinical program studying the over-expression of ICOS in several autoimmune diseases. -- CXCL13 - CXCL13 is a molecule that recruits B cells into inflammatory cell aggregates called follicles. In patients with rheumatoid arthritis the levels of CXCL13 are elevated within the inflamed joints thus encouraging B cells to accumulate and interact with a range of cells, such as T cells, within the joint promoting the generation of new inflammatory follicles and contributing to the disease process.
SOURCE MedImmune
